新生血管性年龄相关性黄斑变性按需治疗方案中获得延长缓解的相关因素
该回顾性病例对照研究纳入830只接受PRN抗VEGF单药治疗的新生血管性年龄相关性黄斑变性眼,77只(9.2%)在中位随访236周内达到延长缓解。基线孤立性视网膜内积液者达到延长缓解更早,3型脉络膜新生血管、较薄脉络膜及无黄斑萎缩增加达到延长缓解的可能性。
要点
- 830只PRN抗VEGF治疗眼中77只(9.2%)达到延长缓解,中位随访236周。
- 基线孤立性视网膜内积液与更早达到延长缓解相关(HR 2.05)。
- 3型脉络膜新生血管、较薄脉络膜及无黄斑萎缩与更可能达到延长缓解相关。
核心结论
- PRN方案治疗新生血管性年龄相关性黄斑变性中9.2%患者可达到延长缓解,基线视网膜影像解剖特征可能预测达到延长缓解的可能性及更短的达到时间。
研究设计与样本
- 回顾性病例对照研究,连续纳入830只接受PRN抗VEGF单药治疗的新生血管性年龄相关性黄斑变性眼,匹配未达到延长缓解的患者作为对照组。
主要发现
- 830只接受抗VEGF单药治疗眼中77只(9.2%)在中位随访236周(范围70-525周)内达到延长缓解。
- Cox回归显示基线孤立性视网膜内积液眼达到延长缓解更早(HR 2.05,95%CI 1.929至4.520,p=0.045)。
- Logistic回归显示基线3型脉络膜新生血管(OR 0.090,95%CI 0.021至0.382,p=0.001)增加达到延长缓解的可能性。
- Logistic回归显示基线较薄脉络膜(OR 0.993,95%CI 0.988至0.998,p=0.004)增加达到延长缓解的可能性。
- Logistic回归显示基线无黄斑萎缩(OR 0.233,95%CI 0.065至0.839,p=0.026)增加达到延长缓解的可能性。
关键数值与推荐
- 延长缓解定义为停止抗VEGF治疗后52周内无出血、光学相干断层扫描无视网膜内/视网膜下积液且荧光素血管造影无渗漏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol. METHODS: This was a retrospective case-control study of a consecutive series of patients with nAMD treated with a PRN antivascular endothelial growth factor (anti-VEGF) drug regimen. ER was defined as the absence of haemorrhage, intraretinal/subretinal fluid on optical coherence tomography and leakage on fluorescein angiography for 52 weeks after cessation of anti-VEGF therapy. Matching patients with nAMD who did not achieve ER were included as control group. Cox regression analysis was fitted to identify predictors of time to achieve ER and time to recurrence. A logistic regression analysis of baseline characteristics was used to identify predictors of achieving ER. RESULTS: Of 830 eyes treated with anti-VEGF monotherapy, 77 (9.2%) eyes achieved ER during a median follow-up of 236 weeks (range 70-525 weeks). Cox regression analysis showed that ER was achieved earlier in eyes with isolated intraretinal fluid (HR, 2.05; 95% CI 1.929 to 4.520; p=0.045) at presentation. Logistic regression analysis showed that type 3 choroidal neovascularisation (OR, 0.090; 95% CI 0.021 to 0.382; p=0.001), thinner choroid (OR, 0.993; 95% CI 0.988 to 0.998; p=0.004) and absence of macular atrophy (OR, 0.233; 95% CI 0.065 to 0.839; p=0.026) at baseline increased the likelihood of achieving ER. CONCLUSION: ER is achievable in 9.2% of patients under PRN therapy for nAMD. At presentation with nAMD, anatomical features on retinal imaging may predict the likelihood of achieving ER and a shorter time to achieve ER.
引用
- Lin T, Dans KC, Muftuoglu IK, et al. Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. Br J Ophthalmol. 2019. PMID: 31302628. doi:10.1136/bjophthalmol-2018-313447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。